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Lymphocyte trafficking is critically regulated by the
Sphingosine 1-phosphate receptor-1 (S1P1), a G
protein-coupled receptor that has been highlighted
as a promising therapeutic target in autoimmunity.
Fingolimod (FTY720, Gilenya) is a S1P1 receptor
agonist that has recently been approved for the
treatment of multiple sclerosis (MS). Here, we report
the discovery of NIBR-0213, a potent and selective
S1P1 antagonist that induces long-lasting reduction
of peripheral blood lymphocyte counts after oral
dosing. NIBR-0213 showed comparable therapeutic
efficacy to fingolimod in experimental autoimmune
encephalomyelitis (EAE), a model of human MS.
These data provide convincing evidence that S1P1
antagonists are effective in EAE. In addition, the
profile of NIBR-0213 makes it an attractive candidate
to further study the consequences of S1P1 receptor
antagonism and to differentiate the effects from
those of S1P1 agonists.
INTRODUCTION
The role of sphingosine 1-phosphate (S1P) in lymphocyte traf-
ficking and immune-related disorders has been extensively
studied (Brinkmann, 2007; Brinkmann and Lynch, 2002; Schwab
and Cyster, 2007). In particular, the S1P receptor subtype 1
(S1P1) has been shown to promote egress of lymphocytes
from lymph nodes (Matloubian et al., 2004). Conditional deletion
of S1P1 from hematopoietic cells reduces the peripheral blood
lymphocyte (PBL) counts by preventing lymphocyte egress
from lymphoid organs. In addition, T cells expressing internaliza-
tion deficient S1P1 show enhanced egress rates (Thangada
et al., 2010). Similarly, the S1P receptor agonist fingolimod
(FTY720, Gilenia) downregulates S1P1, suggesting that it may
act as a functional antagonist of S1P1 to abrogate S1P-driven
migration and prevent egress (Matloubian et al., 2004). Following
this concept, S1P1 antagonism would be expected to have
similar consequences on lymphocyte egress. However, prelimi-1142 Chemistry & Biology 19, 1142–1151, September 21, 2012 ª201nary studies withW146 (Sanna et al., 2006) and VPC44116 (Foss
et al., 2007) suggested that systemic administration of S1P1
antagonists may not affect PBL counts. The proposed explana-
tion for this discrepancy was that S1P1 agonists act on S1P1 on
endothelial cells and potentiate the effect of endogenous S1P in
tightening the endothelial barrier, leading to lymphocyte seques-
tration in peripheral lymphoid organs. In line with this hypothesis,
the S1P1 antagonist W146 reduced endothelial barrier function
and capillary integrity in mouse skin and lung (Sanna et al.,
2006). Recently, we (Berst et al., 2007) and others (Fujii et al.,
2012a, 2012b; Tarraso´n et al., 2011) have demonstrated that
different classes of S1P1 antagonists can induce a reduction of
PBL counts. These studies reconciled the initial discrepancy
between the genetic and pharmacological studies and strongly
suggested that fingolimod acts as a functional antagonist in
controlling lymphocyte trafficking.
Fingolimod demonstrated clinical efficacy in multiple sclerosis
(MS) (Comi et al., 2010; Cohen et al., 2010; Kappos et al., 2006,
2010), and has recently been approved in the United States,
Europe, and other countries for this indication (Brinkmann et al.,
2010). The effect of S1P1 antagonists on PBL counts prompted
us to determine their potential inMS in comparison to fingolimod.
Here, we report the discovery of NIBR-0213, an S1P1 antago-
nist that has comparable efficacy with fingolimod in therapeutic
mouse experimental autoimmune encephalomyelitis (EAE), a
model of human MS (Foster et al., 2007; Kataoka et al., 2005;
Rossi et al., 2012). NIBR-0213 is a highly potent and selective
S1P1 antagonist with very good pharmacokinetic (PK) properties
and, to our knowledge, the first S1P1 antagonist with a long
lasting effect on lymphocyte egress after oral dosing. The overall
profile of NIBR-0213 makes it an attractive candidate to further
study the consequences of S1P1 receptor antagonism, and to
differentiate these effects from those obtained with classical
S1P1 agonists.
RESULTS
Discovery of NIBR-0213
Oral administration of 100 mg/kg of 1 (Figure 1A) (Berst et al.,
2007) reduced PBL counts up to 12 hr, with a maximal effect
of 80%–85% (Figure 2A), which was similar to the effect of
TASP0277308, another S1P1 antagonist, at the same dose
(Fujii et al., 2012a). In order to compare the efficacy of a S1P12 Elsevier Ltd All rights reserved
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Figure 1. Schematic Representation of the
Optimization Leading to the Discovery of
NIBR-0213
(A) Starting points of the optimization.
(B) Prototypic compounds used to test the
potential of replacing the sulfonamide moiety to
improve PK properties.
(C) Further optimization of the potency.
(D) Discovery of NIBR-0213 and its diastereo-
isomer.
See also Figures S2, S3, S4, S5, and S6.
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An S1P1 Antagonist with Efficacy in EAEantagonist in an EAE model with that of fingolimod, we antici-
pated that we would need to achieve a sustained blockage of
lymphocyte egress over the duration of the experiment and at
a dose compatible with chronic dosing. This required a signifi-
cant improvement of the PK properties of 1 that showed low
oral bioavailability and high clearance (Table 1).
Our working hypothesis was that a high polar surface area
(PSA) in combination with the presence of a carboxylic acid func-
tion was responsible for the limited oral bioavailability and high
clearance of 1 (Table 1) (Bo¨cker et al., 2010). This hypothesis
was strengthened by testing the weak analog 2 (Figure 1A), lack-
ing the carboxylic acid function, which showed improved PK
properties with a high oral bioavailability and reduced clearance
(Table 1). However, attempts to replace the carboxylic acid func-
tion led to a dramatic loss of potency (data not shown) and we
decided to focus our efforts on replacing the sulfonamide func-
tion with the aim of reducing the PSA.
To rapidly test the potential of this strategy, we designed a set
of three prototypic compounds (Figure 1B) in which the sulfon-
amide moiety was replaced by a methylene (3), an amide (4),
and an indane (5) linker. All three compounds have a significantly
reduced PSA compared to the parent compound 1 (Table 1).
These compounds were significantly less potent S1P1 antago-
nists than 1, with 3 and 5 retaining modest antagonistic activity,
whereas 4was only marginally active (Table 2). Nevertheless, we
decided to measure the PK properties of these compounds to
see if they had any advantage over 1 and if further efforts should
be invested.
Table 1 shows that compound 3 and 4 both showed low oral
availability and high clearance, leading to verymodest oral expo-
sure. On the contrary, 5 showed a good PK profile with a reduced
clearance around 21 ml 3 min1 3 kg1 and high oral bioavail-
ability. We then set out to improve further on 5 in order to achieve
a similar potency as 1while keeping the attractive PK properties.
Because 3 and 5 had comparable PSA values, we hypothesizedChemistry & Biology 19, 1142–1151, September 21, 2012 ªthat the improved PK properties could
be linked to the a-substitution on the
benzylic carbon. With this in mind, a
possible way to improve the potency
was to reduce the geometrical constraint
imposed by the indane ring of 5 that might
impair the adaptivity of the molecule.
The less rigid analog 6 with a simple
a-methyl substituent (Figure 1C) had sig-
nificantly improved potency, with an IC50
of 4 nM in theGTPg35Sassay and retainedanacceptable PKprofile (Table 1).Of the twodiastereoisomers of
6, NIBR-0213 was the most potent with an IC50 of 2 nM in the
GTPg35S assay (Table 2) that is comparable to the potency
of 1. The stereochemistry of NIBR-0213 was determined by
X-ray (see Supplemental Experimental Procedures available
online). The other diastereoisomer 7 displayed a weaker
antagonistic activity, with 320 nMpotency in the sameassay indi-
cating a degree of stereospecificity in the S1P1 antagonism. The
PK properties of NIBR-0213 showed a moderate clearance
(26 ml 3 min1 3 kg1) and a high oral bioavailability (69%),
leading to significant exposure after oral dosing (Table 1).
NIBR-0213 Is a Potent and Selective S1P1 Antagonist
In Ca2+ mobilization assays, NIBR-0213 displayed an inhibitory
activity on hS1P1 with an IC50 of 2.5 nM whereas it was inactive
(IC50 > 10 mM) on S1P2, S1P3, and S1P4 (Figure 3A). In GTPg
35S
assays, NIBR-0213 displayed potent and comparable potency
on human and rat S1P1 (IC50 of 2.0 nM and 2.3 nM, respectively),
whereas on mouse S1P1 a slightly reduced IC50 of 8.5 nM
was measured. NIBR-0213 showed an 3,000-fold selectivity
against human S1P5 in the GTPg
35S assay (Figure 3A). On
S1P4, a weak agonistic activity was detected with an EC50 of
245 nM (data not shown). Schild plot analysis indicated that
NIBR-0213 is a competitive S1P1 antagonist with a calculated
Kd of 0.37 ± 0.031 nM (Figure 3B).
As shown in Figure 3C, 1 mM NIBR-0213 inhibited FTY720-
phosphate-induced S1P1 internalization whereas treatment with
NIBR-0213 alone did not induce S1P1 internalization up to
100 mM.
NIBR-0213 Does Not Activate GIRK Channels in Atrial
Myocytes
As opposed to S1P (Bu¨nemann et al., 1995) and S1P1 agonists
(Koyrakh et al., 2005), NIBR-0213 does not activate G protein-
coupled inwardly-rectifying potassium (GIRK) channels activity2012 Elsevier Ltd All rights reserved 1143
Figure 2. Pharmacodynamic and Pharma-
cokinetic Effects of Compounds 1, 7, and
NIBR-0213 in the Rat
Changes in PBL counts and drug blood levels
observed in rats treated orally with compound 1, 7,
or NIBR-0213 (n = 3 each, mean ± SEM).
(A and B) Compound 1, 7, and NIBR-0213 were
given at 100, 30, and 30 mg/kg, respectively to
Lewis rats.
(C and D) NIBR-0213 was given at 1, 3, 10, and
30 mg/kg to Wistar rats.
(E and F) Dose-related reduction in PBL counts (E)
and changes in EBD accumulation in lungs (F)
observed in Lewis rats at 6 hr after oral treatments
with NIBR-0213.
Each bar represents an independent treatment
group (n = 3–10, mean ± SEM). See also Figure S1.
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An S1P1 Antagonist with Efficacy in EAEin guinea pig atrial myocytes (Figure 3D). Recording of mem-
brane current from an atrial myocyte after superfusion with
NIBR-0213 at 30 mM showed a nonsignificant GIRK current
increase of 1.1% ± 4 .0%, as compared to the marked effect
with 20 mM acetylcholine (Ach). This result is in line with the
antagonistic activity of NIBR-0213 that does not induce S1P1-
mediated intracellular signaling.
NIBR-0213 Efficiently Reduces PBL Counts with
a Prolonged Duration of Action
As shown in Figure 2A,NIBR-0213given orally at 30mg/kg to rats
reduced the PBL counts by 75%–85% within 14 hr and main-
tained this effect up to 24 hr posttreatment. This is in sharp
contrast to compound 1 that, at 100 mg/kg orally, was able to
reduce the PBL counts by 75%–85% up to 12 hr only and was
ineffective 24 hr posttreatment. This longer duration of action
for NIBR-0213 is most likely due to a more favorable PK profile
(Table 1), with blood levels R100 ng/ml (i.e., 215 nM) up to
24 hr posttreatment (Figure 2B). Interestingly, such high blood1144 Chemistry & Biology 19, 1142–1151, September 21, 2012 ª2012 Elsevier Ltd All rights rlevels couldnotbeachievedby thediaste-
reoisomer compound 7 at 30mg/kg orally
(Figure 2B), suggesting a stereospecific
absorption/metabolism in the rat. Under
those conditions, compound 7 failed to
impact the PBL counts, which is presum-
ably due to both the lower exposure and
the weaker in vitro potency of this com-
pound as compared to NIBR-0213.
Importantly, the duration of action of
oral NIBR-0213 on the reduction of rat
PBL counts was dose-dependent, with
a maximal effect (Emax) of 75%–85%
versus baseline achieved after 4 hr and
lasting up to 7, 14, and 24 hr posttreat-
ment with 3, 10, and 30 mg/kg, respec-
tively (Figure 2C). Based on the dose-
dependent exposure profiles illustrated
in Figure 2D, it could be estimated that
blood levels of at least 20–60 ng/ml (i.e.,
40–120 nM) are necessary for NIBR-
0213 to maintain its Emax up to 24 hr.Knowing that its Emax on rat PBL occurs within 6 hr posttreat-
ment, a wide dose-range of NIBR-0213 was tested to estimate
its ED50 value (effective dose reducing PBL by 50%). Under
those conditions, the lowest dose required to achieve Emax
was 1 mg/kg and the ED50 for NIBR-0213 was estimated to
be 0.2 mg/kg (Figure 2E).
NIBR-0213 Increases Surface Expression of CD69 on
Single Positive Thymocytes
Mice treated with NIBR-0213 showed an increase of CD69 sur-
face expression in single positive CD4 and CD8 thymocytes
(see Supplemental Experimental Procedures and Figure S1).
The effect was particularly prominent on single positive CD8 cells
(70% CD69high in the b7-integrin positive cells in Figure S1D).
Fingolimod-treated animals show a general reduction of CD69
staining. The effect of NIBR-0213 was consistent with what was
observed for TASP0277308, a S1P1 antagonist of a different
scaffold (Fujii et al., 2012a), whereas the effect of fingolimod
resembled that reported for S1P1 agonists (Alfonso et al., 2006).eserved
Table 1. Pharmacokinetic Properties of Compounds 1 to 6 and NIBR-0213
1a 2b 3b 4b 5b 6b NIBR-0213a
I.v. dose (mg 3 kg1)c 1 1 1 1 1 1 1
CL (ml 3 min1 3 kg1) 145 26 52 111 21 76 26
VSS (l/kg) 10.2 1.16 3.7 5.7 5.5 13.3 11.4
T1/2 (h) 1.9 1.06 1.4 0.8 6.2 2.7 5.3
AUC0-N d.n. (nmol 3 h 3 l
1)d 258 1,453 796 400 1,872 472 1,450
Oral dose (mg 3 kg 1)e 3 3 3 3 3 3 3
AUC0-N d.n. (nmol 3 h 3 l
1)d 29 1,580 49 n/a 1,289 387 958
F (%) 11 109 6 n/a 69 82 69
Cmax d.n (nM) 4 161 20 1 139 43 87
Tmax (h) 1.1 5.3 1.1 0.4 3.9 2.1 1.4
PSA 113 75 78 96 70 78 78
CL, total plasma clearance; VSS, volume of distribution at steady state; T1/2, elimination half life; F, oral bioavailability; PSA, polar surface area.
aOne-in-one experiment experiments.
bCassette experiments.
cI.v. formulation are as follows: 30% N-methyl-2-pyrrolidone and 70% polyethylene glycol.
dAUC0-N d.n.: area under the curve extrapolated to infinity, dose normalized.
eOral formulation are as follows: 0.5% Tween80 and 0.5% carboxymethyl cellulose in water.
Table 2. Potency of the Reported Compounds on Human S1P1
IC50 (nM) HeLa CaFLIPR (hS1P1) GTPgS-assay (hS1P1)
1 1.05 ± 0.36 2.6 ± 0.06
2 850 ± 220 2,800 ± 525
3 170 ± 63 4,270 ± 1,380
4 8,330 ± 1,230 >10,000
5 210 ± 57 1,990 ± 650
6 6.0 ± 0.58 4.3 ± 0.72
NIBR-0213 2.5 ± 0.56 2.0 ± 0.33
7 14 ± 4.8 320 ± 87
In the Ca2+ mobilization assay (FLIPR) the inhibition of the transient
increase in intracellular Ca2+ by the S1P1 selective agonist AUY954
(Zhang et al., 2009) was measured using a HeLa cell line expressing
hS1P1 and Ga16. For the GTPgS assay membranes of a CHO cell line
transfected with hS1P1 were used and the inhibition of GTPgS binding
measured in the presence of S1P. The IC50 was calculated as half
maximal inhibition. Each IC50 value is the average of at least three
measurements (± SEM).
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An S1P1 Antagonist with Efficacy in EAENIBR-0213 Increases the Vascular Permeability in Rat
Lungs
As S1P1 antagonists have been shown to induce capillary
leakage in rodent lungs (Fujii et al., 2012a; Sanna et al., 2006),
we sought to investigate the effects of NIBR-0213 in an Evans
blue dye (EBD) lung leakage model (Sanna et al., 2006). As illus-
trated in Figure 2F, NIBR-0213 increased in a dose-dependent
manner the leakage of plasma proteins into lung parenchyma,
as measured by the increase in EBD in lung tissues at 6 hr post-
treatment (time of Emax on PBL). A maximum of 4–5-fold EBD
increase versus vehicle controls was observed with 0.3 mg/kg.
An ED50 of 0.1 mg/kg could be estimated, i.e., in the range of
the ED50 for the effects on PBL counts.
NIBR-0213 Is as Efficacious as Fingolimod when Given
Therapeutically in a Mouse EAE Model
As a prerequisite prior to this study, it was confirmed that oral
NIBR-0213 at 30 mg/kg was able to reduce PBL by 86% ± 7%
over 24 hr in naive mice (n = 3). However, as the efficacy and
tolerability of repeated oral NIBR-0213 treatments in diseased
mice were unknown, it was considered safer for the mice to start
treatment with an induction dose of 30mg/kg twice per day (BID)
for 3 days and then, if possible, optimize the conditions for effi-
cacy by increasing the dosing to 60 mg/kg BID for the remainder
of the experiment. Under such conditions, the NIBR-0213 treat-
ment waswell tolerated and no unexpected adverse events were
observed until the end of the study at posttreatment day 26.
As shown in Figure 4A, therapeutic NIBR-0213-treatment (i.e.,
starting at the peak of disease) resulted in a gradual reduction in
disease-scores, with a divergence from vehicle controls that
became significant after 5 days (n = 10). This beneficial effect ap-
peared similar to the one obtained, in an independent study, with
therapeutic fingolimod given orally at 3 mg/kg once a day (QD)
(Figure 4B). In parallel, both NIBR-0213- and fingolimod-treated
animals showedmarkedly reduced initial weight loss followed by
a faster and stronger weight gain versus vehicle controls (FiguresChemistry & Biology 19, 1142–1154C and 4D). At termination, the clinical scores observed in the
NIBR-0213- and fingolimod-groups were reduced by 62% and
61% versus pretreatment, respectively. In contrast, a reduction
of 19% and 17% only was observed in the respective vehicle
control groups.
The NIBR-0213 levels measured 6 hr after the last dose in
whole blood at termination day were 1,862 ± 184 ng/ml. This
confirms that the NIBR-0213 regimen used achieved peak blood
drug levels far above the 100 ng/ml range that was considered as
the lower limit for optimal PBL reduction.
The development of EAE is known to be associated with
a marked reduction in PBL counts (MacPhee et al., 1989).This
was confirmed in the present study, as the PBL levels measured
in all vehicle controls were markedly reduced (3- to 4-fold)
as compared to the PBL levels in naive mice (6,187 ± 1,3011, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1145
Figure 3. In Vitro Characterization of
NIBR-0213
(A) S1P receptor profile of NIBR-0213: IC50 values
for NIBR-0213 in GTPgS and Ca2+ mobilization
assays. Each IC50 value is the average of at least
three measurements (mean ± SEM).
(B) Schild plot analysis of NIBR-0213 using the
S1P1 agonist AUY954 in the GTPg
35S assay.
(C) FTY720-phosphate-induced S1P1 receptor
internalization. Internalization of S1P1 receptor in
CHO cells treated with either FTY720-phosphate
alone at 10, 100, or 1,000 nM (n = 3, mean ± SEM),
NIBR-0213 alone at 1,000 nM (n = 2), or NIBR-
0213 at 1,000 nM followed by FTY720-phosphate
at 100 nM (n = 2).
(D) GIRK channel activation: representative re-
cording of membrane current from an atrial
myocyte after superfusion with 30 mM NIBR-0213
compared to 20 mM Ach. Mean GIRK current
amplitudes were normalized to responses evoked
by 20 mMACh in the same cell (n = 4; mean ± SEM).
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An S1P1 Antagonist with Efficacy in EAEcells/ml; n = 8). Under such circumstances, NIBR-0213-treated
mice showed a further reduced number of PBL versus vehicle
controls, although the difference did not reach the level of statis-
tical significance, due to the already low lymphocyte counts in
control animals. This is, however, most likely reflecting a biolog-
ically relevant and optimal effect for NIBR-0213 as similarly low
PBL levels were observed in fingolimod-treatedmice (Figure 5A).
In addition, blood neutrophil and monocyte counts were not
affected by NIBR-0213 and fingolimod treatments.
Examination of the spinal cord tissue demonstrated a signifi-
cant decrease in inflammation (as revealed by H&E staining)
and loss of myelin (as revealed by solochrome staining) in
NIBR-0213-treated mice versus vehicle controls. There was
also a trend for a reduced macrophage/microglia activation
(as revealed by Iba-1 staining) in NIBR-0213-treated mice but
this effect did not reach statistical significance. Representative
examples are shown in Figures 5B–5D together with the corre-
sponding mean pathological scores. Interestingly, similar pro-
tection was observed in fingolimod-treated mice although, in
this case, associated with a significant reduction in macro-
phage/microglia activation.1146 Chemistry & Biology 19, 1142–1151, September 21, 2012 ª2012 Elsevier Ltd All rights rDISCUSSION
S1P1 antagonists reported so far have
suboptimal oral bioavailability and/or
require high doses to achieve a moderate
duration of action in reducing PBL counts
(Tarraso´n et al., 2011; Berst et al., 2007;
Fujii et al., 2012b, 2012a). This presum-
ably prevented the broad profiling of
these compounds in autoimmune dis-
ease models, and so far, efficacy was
only demonstrated in a prophylactic
collagen-induced arthritis model (Fujii
et al., 2012a). Here, we report the
discovery and characterization of NIBR-
0213 that (1) is a potent and competitive
S1P1 antagonist, (2) is selective for S1P1
over other S1P receptor subtypes, and (3) has good pharmaco-
kinetic properties that lead to significant blood exposure after
oral dosing in rodents with long lasting effects on PBL. These
properties allowed us to demonstrate that a competitive S1P1
antagonist has therapeutic efficacy in an EAE model.
The results show comparable efficacy for NIBR-0213 and
fingolimod in a well-established mouse chronic nonremitting
EAE model (Oliver et al., 2003; Rossi et al., 2012; Kataoka
et al., 2005) for the main parameters measured: reduction of
disease scores and body weight recovery over time as well as
reduced spinal cord inflammation and loss of myelin. In this
model, the treatment was initiated therapeutically, i.e., after
symptoms were established, thus allowing the immune system
to respond to the autoantigen MOG and establish the disease,
unlike prophylactic treatment. NIBR-0213 treatment had similar
impact on PBL counts as compared to treatment with fingoli-
mod, without significant effect on monocytes and neutrophils,
indicating that the innate immune system remained unaffected
by NIBR-0213 treatment. This supports the hypothesis that
S1P1 antagonists have similar therapeutic potential versus
S1P1 agonists for the treatment of multiple sclerosis, despiteeserved
Figure 4. Efficacy of NIBR-0213 and Fingoli-
mod in a Mouse Therapeutic EAE Model
Monitoring of daily EAE clinical scores (A and B)
and changes in body weights (C and D) observed
in MOG/CFA/Pertussis toxin-treated mice C57BL/
6 mice. At peak of disease, the mice were treated
orally with either NIBR-0213 (A and C), fingolimod
(B and D), or their respective vehicle (n = 10 each,
mean ± SEM).
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An S1P1 Antagonist with Efficacy in EAEtheir different mechanism of action at the level of the S1P1
receptor. The results also strongly suggest that the efficacy of
fingolimod in EAE may be due to ‘‘functional antagonism’’ rather
than persistent agonism/signaling at the S1P1 receptor.
Although S1P1 antagonists and fingolimod show similar
effects on PBL counts, they act through different mechanisms.
In the case of fingolimod, S1P1-dependent intracellular signaling
is followed by receptor internalization and degradation (Brink-
mann et al., 2010; Oo et al., 2007, 2011; Thangada et al.,
2010). S1P1-signaling is responsible for S1P1-dependent activa-
tion of the G protein-coupled inwardly-rectifying potassium
(GIRK/IKAch) channel in cardiomyocytes that has been associ-
ated with the transient asymptomatic reduction of heart rate
observed in man after the first dose of fingolimod (Koyrakh
et al., 2005) or BAF312, a S1P1,5-selective agonist (Gergely
et al., 2012). In the case of NIBR-0213, there is no S1P1-depen-
dent intracellular signaling, no effect on GIRK channel activity in
atrial myocytes, and no S1P1 internalization. Importantly, NIBR-
0213 fully blocked the S1P1-internalization effect of fingolimod
that is in line with VPC44116, another S1P1 antagonist (Oo
et al., 2007). Finally, NIBR-0213 shows a prominent increase of
the surface expression of CD69 in thymocytes, whereas fingoli-
mod showed a reduction compared to vehicle-treated animals.
These results suggest that S1P1 antagonists have a different
mode of action than that of fingolimod, with possible conse-
quences to potential side effects. NIBR-0213 is, for example,
not expected to cause bradycardia in human, because it is
devoid of any GIRK channel activity. This property cannot,
however, be verified in preclinical models, because the cardiacChemistry & Biology 19, 1142–1151, September 21, 2012 ªeffects of fingolimod in rodents are not
S1P1-dependent as in humans but rather
S1P3-dependent (Forrest et al., 2004;
Gergely et al., 2012; Sanna et al., 2004).
On the other hand, as previously
described S1P1 antagonists, NIBR-0213
induces pulmonary vascular leakage
that has been attributed to the inhibition
of the S1P1 function on vascular endothe-
lial cells (Sanna et al., 2006). In the case of
NIBR-0213, the ED50 for induction of this
leakage is similar to the ED50 for the
reduction of PBL counts, indicating that
the two effects could be tightly linked
to S1P1 antagonism and are unlikely to
be separable. The physiological conse-
quences of such an increased vascular
permeability are not yet known. It was
noted that chronic dosing with NIBR-0213 in the course of the EAE model reported in this study did
not reveal any adverse events related to pulmonary function.
Further safety studies are needed to more specifically explore
the consequences of long-term chronic dosing with an S1P1
antagonist on lung function.
SIGNIFICANCE
The S1P1 receptor is a key regulator of lymphocyte traf-
ficking and has been shown to be an important therapeutic
target in autoimmune diseases. Fingolimod (FTY720, Gile-
nya), an S1P1 agonist, has demonstrated clinical efficacy
for the treatment of multiple sclerosis (MS) and has been
approved for this indication. Fingolimod induces the se-
questration of lymphocytes in lymphoid organs and a reduc-
tion of peripheral blood lymphocyte (PBL) counts. This effect
was attributed to the downregulation of the S1P1 receptor,
indicating that fingolimod acts as a functional antagonist.
Here, we report the discovery of NIBR-0213, a potent and
selective S1P1 competitive antagonist, which in contrast
to previously reported S1P1 antagonists, shows a suitable
pharmacokinetic profile to achieve long lasting reduction
of PBL counts after oral dosing. These properties allowed
us to demonstrate that an S1P1 antagonist is efficacious in
experimental autoimmune encephalomyelitis (EAE), amodel
of human MS. NIBR-0213 shows comparable therapeutic
efficacy to fingolimod in amouse EAEmodel. These findings
support the hypothesis that S1P1 antagonists have similar
therapeutic potential to S1P1 agonists for the treatment of2012 Elsevier Ltd All rights reserved 1147
Figure 5. Hematological and Histological
Changes Observed in the Mouse EAE Study
Peripheral blood lymphocytes, neutrophils, and
monocytes counts at termination in all C57BL/6
mice-EAE groups, as measured by an automated
hematology analyzer (n = 8 each, mean ± SEM) (A).
Histological analysis (representative examples
and scorings) of spinal cord samples collected in
all C57BL/6 mice-EAE groups: H&E staining for
inflammation (B); Iba-1 staining for macrophages/
activated microglia (C); solochrome staining for
loss of myelin (D). Arrows point to areas of
pathology. Scale bar represents 200 mm.
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action. The profile of NIBR-0213makes it an attractive candi-
date to further study the consequences of S1P1 receptor
antagonism and to differentiate the effects from those ob-
tained with S1P1 agonists.
EXPERIMENTAL PROCEDURES
Chemistry
Detailed synthetic schemes, synthetic procedures, and characterization data
are presented in the Supplemental Experimental Procedures.
In Vitro Assays
Ca2+-Mobilization Assay
hS1P1-dependent Ca
2+ mobilization was assessed in hS1P1-transfected
HeLa(Ga16) cells. Cells were loaded with the Ca
2+-sensitive fluorochrome
Fluo-4 (Molecular Probes) in loading buffer (HBSS, 20 mM HEPES, 0.1% fat
free BSA, 2.5 mM Probenecid, 1.6 mM Fluo-4 AM) for 1 hr at 37C. After
washing (HBSS, 20 mM HEPES, 2.5 mM Probenecid), the cells were preincu-
bated with compounds for 20 min at room temperature in assay buffer (HBSS,
20 mM HEPES, 0.1% fat free BSA). The transient increase in intracellular Ca2+
after the addition of the S1P1 selective ligand AUY954 was monitored in a fluo-
rescence image plate reader (FLIPR) instrument. The inhibition of AUY954-
induced Ca2+ mobilization in the presence of hS1P1 antagonists is reported
as IC50 values, i.e., the concentration of compound that reduced the maximal
Ca2+ response to 50%. For hS1P2- and hS1P3-dependent Ca
2+ mobilization
transfected CHO cells were used and for hS1P4 CHO(Ga16) cells; S1P was
used as probing agonist.
GTP [g-35S] Assay
Membranes are prepared from CHO cell clones stably expressing a human
S1P1. The desired amount of membranes (1–5 mg/well) was diluted with assay1148 Chemistry & Biology 19, 1142–1151, September 21, 2012 ª2012 Elsevier Ltd All rights rbuffer (50 mMHEPES, pH 7.4, 5 mMMgCl2, 1 mM
CaCl2, 1% fatty acid-free BSA) containing 10 mM
GDP, 25 mg/ml Saponin, and 5 mg/ml WGA-SPA
beads (Perkin-Elmer).
Serial dilutions of compounds were incubated
with 200 ml membrane-WGA-SPA bead slurry for
15 min followed by the addition of the agonist
S1P. Then GTP [g-35S] (0.2 nM final concentration)
in assay buffer was added. After incubation at
room temperature for 120 min under constant
shaking the plates are centrifuged for 10 min at
1,000 3 g to pellet the membrane-SPA beads
slurry. Then theplates aremeasured in a TOPcount
NXT instrument (Perkin-Elmer). Eight different
concentrations of compound were used to
generate a concentration response curve (using
two data points per concentration) and the corre-
sponding IC50 value using the curve-fitting tool of
GraphPad Prism.S1P2-, S1P3-, S1P4-, and S1P5-dependent GTP [g-
35S] assays were carried
out in a comparable manner to the S1P1 GTP [g-
35S] assay using membranes
from CHO cells stably expressing the S1P receptors.
Receptor Internalization Assay
CHO cells stably expressing N-terminal myc-tagged human S1P1 were culture
in aMEM, 10% charcoal-stripped lipid-depleted fetal bovine serum (FBS),
50 mg/ml Gentamycin, 0.5 mg/ml G418 at 106 cells/ml overnight at 37C in
a CO2 incubator. Compounds at indicated concentrations (in complete
medium) and cells were incubated for 60 min at 37C. Then cells were washed
twice with cold PBS/0.5% BSA. Anti-myc antibody (4 mg/ml of monoclonal
mouse anti c-myc IgG1 (Roche Applied Science) was added and cells incu-
bated for a further 40 min at 4C. Cells were washed in PBS/0.5% BSA and
1 mg/ml of Alexa488-labeled goat anti-mouse secondary conjugates (Molec-
ular Probes, Juro Supply, Luzern, Switzerland) was added. Cells were incu-
bated for 20 min at 4C, washed with PBS/0.5% fatty acid free BSA and
analyzed using flow cytometry. CHO(myc-S1P1) cells were used as negative
control (no internalization) and CHO cell as positive control (no surface
S1P1). After washing the cells, anti-myc antibody and Alexa488-labeled goat
anti-mouse secondary conjugates were used to stain and analyze the cells
by FACS.
Electrophysiological Recordings of GIRK Channels in Atrial
Myocytes
To measure the activity of endogenous GIRK channels, membrane currents
were recorded in guinea pig atrial myocytes using a whole cell voltage-clamp
technique as described previously (Bu¨nemann et al., 1995). For application
of NIBR-0213 to individual cells, a micro perfusion system was used. The
compound was applied in recording buffer and the currents were normalized
to the current induced by a saturating concentration (20 mM) of ACh in the
same cell. GIRK currents were identified by their strongly inward-rectifying
properties. Corresponding currents weremeasured using voltage ramp-proto-
cols and background leak subtraction. A standard holding potential of90mV
was used throughout such that GIRK currents, under this condition, areeserved
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to the amplitude of current evoked by 20 mM ACh through M2 muscarinic
receptors, which yields the maximum GIRK current in each cell (GIRKmax).
In Vivo Experiments
All animal work was performed according to the Swiss federal law for animal
protection and approved by the Veterinary Office Basel.
Effects on Peripheral Blood Lymphocyte Counts in Rodents
Lewis orWistar rats (220–250 g,males, Charles River), or C57BL/6mice (18–20
g, females, Harlan), were treated orally (2–5 ml/kg) with 1, 7, or NIBR-0213 (all
prepared fresh in a 30% PEG/buffer solution). Longitudinal blood sampling
was performed under anesthesia (5 vol % isoflurane; Forene, Abbott) by
sublingual punctures, with 200 ml/sample in EDTA-coated Eppendorf tubes.
All blood cell counts were measured by an automated hematology analyzer
(ADVIA 120, Siemens).
Lung Vascular Permeability in Rats
At 5 hr posttreatment with NIBR-0213, leakage of plasma proteins in the lungs
was assessed using the standard Evans blue dye (EBD)-leakage technique
(Sanna et al., 2006). Briefly, EBD (Fluka) was administered intravenously (i.v.;
20 mg/2 ml NaCl/kg), under anesthesia. One hour later, the rats were bled
under deep anesthesia by incision of the vena cava and the pulmonary vessels
perfused via the right-ventricle with 10 ml of saline to remove blood and EBD
from the vascular spaces. The lungs were removed en bloc and dried at 60C
for 24 hr.
Dried lungs were weighed and immersed into 2 ml formamide (Sigma) for
24 hr at 37C and extracted EBD from each sample was assessed by spectro-
photometry at 620 and 740 nm, to correct for contaminating heme pigments
with the following formula: OD620 (EBD) = OD620 (1.4263OD740 + 0.030).
The EBD concentrations in lung homogenates were finally estimated with
the help of parallel EBD-standard curve.
EAE Model in C57BL/6 Mice
This model was conducted as previously described (Oliver et al., 2003). Briefly,
mice were immunized at with subcutaneous injection on the lower back of
myelin oligodendrocyte glycoprotein peptide (MOG1–125; in house produced;
200 mg/100 ml) emulsified in 4 mg/ml complete Freund adjuvant (CFA, Sigma).
Pertussis toxin (Fluka; 200 ng per mouse) was administered intraperitoneally
on day 0 and day 2. EAE development was monitored daily using the well es-
tablished scoring system (0: normal appearance; 1: complete tail paralysis; 2;
unilateral partial hind limb paralysis; 3: complete bilateral hind limb paralysis; 4:
quadriplegia; 5: death).
Treatments (n = 10/group) started once the mice were on their way to score
3. Prior to treatments, animals were randomized so that all groups were
comparable for clinical profile and body weights. Treatment with NIBR-0213
started with 30 mg/kg twice per day (BID) for 3 days and then increased to
60 mg/kg BID until the remainder of the experiment. In total, the treatment
lasted 26 days. A vehicle (30% PEG/phosphate buffer)-treated group was
run in parallel as negative control.
At study termination, 6 hr postdose, blood was collected in EDTA-coated
tubes via cardiac puncture. Blood cell counts were measured using the ADVIA
120 Hematology System. Blood aliquots were also stored at 80C for latter
processing. Brains were harvested, weighed, snap-frozen in liquid nitrogen,
and stored at 80C.
The same protocol was used to assess, in an independent study, the thera-
peutic effects of fingolimod at 3 mg/kg/day. In this case the vehicle was water.
Effect on CD69 Expression in Thymocytes
FemaleBalb/cWTmice (n=3/group)were treated orally (10ml/kg)with FTY720
(3mg/kgQD), NIBR-0213 (30mg/kg BID), or vehicle (30%PEG 200/phosphate
buffer) and sacrificed after 24 hr for thymus harvesting. Thymocytes were then
isolated by gently disrupting thymus in 5% FBS/phosphate buffer on ice and
passing through a 40-mm nylon mesh. Aliquots of 2–4 106 cells were prepared
and stained with various antibodies for flow cytometry: anti-CD69-Alexa
488 nm (clone H1.2F3; BD Biosciences), anti-b7-integrin-PE (FIB504, Bio-
legend), anti-CD8-PE-Cy5 (53-6.7, BD Biosciences), anti-CD4-allophycocya-
nin-Cy7 (GK1.5, BD Biosciences). For flow cytometry, 0.5 105 cells of each
sample were analyzed and data were processed by standard FCM software.
Histology
Standard techniques were followed to remove the spinal tissue, process and
embed in paraffin and, for each mouse, the spinal cord was divided into fourChemistry & Biology 19, 1142–115cervical pieces and six thoracic/lumbar pieces. Sections were then cut (7
and 10 mm), placed on glass slides, dried at 37C overnight, and stored until
stained. Histochemistry stains for tissue morphology (H&E), myelin (solo-
chrome), and axons (Bielschowsky).
Staining for microglia and macrophages was performed using the rabbit
anti-ionized calcium binding adaptor molecule 1 (Iba) antibody (Wako Chem-
ical Industries, Osaka, Japan; catalog number 019-19741). Sections were
dewaxed, hydrated, and antigen retrieval performed using citrate buffer pH
6.0 at a temperature of 98C for 30 min. Slides were allowed to cool, peroxi-
dases blocked (Perox Block Flex, Dakocytomation, Baar, CH) and primary
antibody applied (dilution 1:1,000) for 30 min. The remainder of the protocol
was performed using the Dako Envision Flex DAB+ kit.
Sections were examined and scored blinded. At least five separate cervical
and thoracic sections were quantified per animal. A semiquantitative scoring
system was established for all of the stains in which 0 = no observable
changes, 1 = minimal, 2 = moderate, 3 = major, and 4 = severe. All scores
for the respective spinal cord areas were averaged for individual mice and
then pooled in the vehicle or treatment group.
Statistical Analysis
Clinical score comparisons between treatment groups were evaluated on
a daily basis and compared to vehicle control. All statistical analyses of clinical
score parameters used a Mann-Whitney rank sum test. For body weight
comparisons and lymphocyte analysis a parametric Student’s t test was
utilized.
For histology results, the average and standard error of the mean were
calculated. A Mann-Whitney nonparametric t test was performed to compare
NIBR-0213-treated to vehicle-treated mice. All graphs are shown as mean ±
SEM. All statistical analysis was performed using GraphPad Prism version
5.00 for Windows, (GraphPad Software, San Diego, CA).
Drug Levels Determination in EAE and PBL Experiments
Whole blood samples were mixed with internal standard (20 ml) and acetonitrile
(400 ml). After ultrasonication, vortexing, and centrifugation, supernatant were
collected (375 ml) and evaporated till dryness. The residues were dissolved in
acetonitrile 50% (30 ml) and water (30 ml), well stirred, ultrasonicated, and
centrifuged. An aliquot of each sample (50 ml) was transferred to mHPLC vials
and stored at 10C till analysis. For analysis, 10 ml of each sample was injected
on a 0.5 mm 3 50 mm Kromasil 100-C18 column (Eka Chemicals AB, Bohus,
Sweden), filled with 3.5 mm particles. For separation, a linear gradient from 0%
B in A to 95% B in A in 6 min at a flow rate of 20 ml/min was applied. Buffer A
was 10 mM NH4OAc in water with 0.02% acetic acid and buffer B was 95%
acetonitrile with 0.02% acetic acid. For detection, the column effluent was
directly guided to an AP-ESI source of a triple quadrupole mass spectrometer
run in negative MRM. For NIBR-0213, the [M-H]-ion was isolated and the
mass transition 463.1 > 195.2 was used. The quantification was based on
compound/internal ratio of the extracted ion chromatograms applying a
second order fitted, zero included and 1/3weighted calibration curve covering
the concentration range between 1 ng/ml up to 10,000 ng/ml. Recovery, accu-
racy, and precision was within the accepted range and the LOQ was deter-
mined to be 1 ng/ml.
Pharmacokinetic Experiments
Independently if cassette or one-in-one setting was applied, the experiments
were performed in conscious, fed, permanently cannulated rats kept under
standard conditions. For oral administration by gavage, a mixture of 0.5%
N-methyl-pyrrolidone with 0.5% carboxymethyl-cellulose in water was used
as a vehicle (5 ml/kg), whereas for the i.v. route compounds were administered
into the femoral vein as a solution in N-methyl-2-pyrrolidone (30%) in polyeth-
ylene glycol 200 (0.5 ml/kg). Blood samples 70 ml were collected from the
femoral artery for 24 hr after i.v. administration and for 7 hr after oral dosing.
I.v. and oral (p.o.) administration was in the same animals with a 48 hr washout
period between administrations. After acetonitrile precipitation of whole blood
samples, dried residues were redissolved in methanol/water, analyzed by
HPLC on a C18 reversed-phase HPLC column. Eluents were A: 100% water,
B: 100% acetonitrile, or methanol and in both formic acid for positively
charged and ammonia for negatively charged compounds was added as
modifier. A adapted linear gradient was run from A to B over 7.5 min at
a constant temperature of 50C in the column compartment. Sample injection
volume was 10 ml. The flow from the HPLC systemwas directly introduced into
the ion source of a Waters Quatro Ultima triple quadrupole mass analyzer and1, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1149
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tive mode). All compounds were detected as protonated [M+H]+ respectively
deprotonated. [MH] quasimolecular ions. Structurally closely related
compoundswere used as analytical internal standards. Quantification of blood
levels of the parent compounds was based on a 7-level calibration curve (in
triplicate) using blank rat blood samples spiked with stock solutions of external
and internal standards. Pharmacokinetic parameters were estimated using
a noncompartmental approach. Area under the curves i.v. and p.o. were calcu-
lated using the trapezoidal rule, then extrapolated to infinity using the terminal
half-life calculated from the last three (measurable) blood levels after i.v.
administration.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/10.
1016/j.chembiol.2012.07.016.
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